AccurKardia announced today that the FDA granted 510(k) clearance for its cloud-based electrocardiogram (ECG) interpretation software.
The AccurECG analysis system, a device-agnostic, fully automated platform, offers a wide range of benefits in ECG interpretation. It features beat-by-beat analysis, ventricular/supraventricular ectopic beat detection and heart rate measurement. The system offers automated interpretation of 13 different heart rhythms, including sinus tachycardia, sinus bradycardia, AFib and atrial flutter.
AccurKardia said that AccurECG provides Lead II analysis of data obtained from compatible ECG devices with wet electrodes. These include Holter monitors, event recorders and/or cardiac telemetry devices. Its fully automated output improves clinicians’ review efficiencies and enables the prompt treatment of patients. AccurKardia says it delivers results in just minutes.
Other benefits include customizable outputs and configurations,…